Trials / Unknown
UnknownNCT05473468
Single Dose Study To Study The Absorption, Metabolism And Excretion Of Famitinib
A Single Center, Single Dose, Open Label Phase 1 Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance And Metabolism Of [14c]-Famitinib In Healthy Adult Male Subjects
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the excretion balance, metabolic profile and the routes of excretion of famitinib in healthy adult male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Famitinib | a single oral dose of \[14C\]famitinib (25 mg/150 uCi suspension) |
Timeline
- Start date
- 2022-08-26
- Primary completion
- 2022-11-01
- Completion
- 2022-11-01
- First posted
- 2022-07-26
- Last updated
- 2022-11-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05473468. Inclusion in this directory is not an endorsement.